国产精品丁香六月激情网,_中文字幕丁香五月天婷婷激情六月_欧美精品天天插日日操_中文字幕久久婷婷五月综合色丁香花_日韩精品激情婷婷丁香色五月综合深爱野花_亚洲无码狠狠色丁香婷婷综合_日韩精品五月天激情国产综合婷婷婷_日韩精品亚洲婷婷在线观看

今天(tiān)是(shì)2026年(nián)7月22日(rì) 星期三(sān),歡迎(yíng)光(guāng)臨(lín)本(běn)站 上(shàng)海研生(shēng)實(shí)業有限公(gōng)司 網址(zhǐ): darylliu.cn

標記(jì)一抗

FITC標記(jì)的肌萎縮側(cè)索(suǒ)硬化蛋白2抗體(tǐ)

文(wén)字:[大(dà)][中][小] 2017-5-2    瀏(liú)覽次數(shù):1394    

                                     FITC標(biāo)記的(dí)肌(jī)萎(wěi)縮側索(suǒ)硬化蛋(dàn)白(bái)2抗體(tǐ)                                                                                                                                                
英文名(míng)稱Anti-ALS2/FITC
中文(wén)名(míng)稱:FITC標(biāo)記的肌萎縮側索(suǒ)硬化蛋(dàn)白(bái)2抗體
別    名ALS 2; ALS2; ALS2_HUMAN; ALS2CR6; Alsin; ALSJ; Amyotrophic lateral sclerosis 2 (juvenile); Amyotrophic lateral sclerosis 2 (juvenile) chromosome region candidate 6; Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 6 protein; Amyotrophic lateral sclerosis 2 protein; Amyotrophic lateral sclerosis protein 2; FLJ31851; IAHSP; KIAA1563; MGC87187; PLSJ.  

詳(xiáng)細(xì)介紹(shào):


規(guī)格:100ul 
說(shuō) 明(míng) 書100ul  
研究領域細胞生物  神經生物學(xué)  Alzheimer's  
抗(kàng)體來源Rabbit
克隆(lóng)類型(xíng)Polyclonal
交叉反應 Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, Sheep, 
產品應(yīng)用ICC=1:50-200 IF=1:50-200  
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分(fēn) 子(zǐ) 量(liáng)184kDa
性    狀Lyophilized or Liquid
濃    度(dù)1mg/ml
免(miǎn) 疫 原KLH conjugated synthetic peptide derived from human ALS2 (1384-1440aa)
亞    型IgG
純(chún)化(huà)方(fāng)法(fǎ)affinity purified by Protein A
儲 存 液(yè)0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保(bǎo)存條件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

相關資(zī)料:


產品介(jiè)紹(shào)background:
Mutations in the ALS2 gene result in a number of juvenile recessive motor neuron diseases (MNDs), including juvenile primary lateral sclerosis (JPLS), a recessive form of amyotrophic lateral sclerosis (ALS2); infantile onset ascending hereditary spastic paralysis (IAHSP); and a form of complicated hereditary spastic paraplegia (cHSP). The ALS2 gene encodes the Alsin protein. Alsin acts as a guanine nucleotide exchange factor for Rab5, a modulator of the endocytic pathway. Alsin is a cytosolic protein that is associated with small, punctate membrane structures. Therefore, Alsin may mediate membrane transport events, potentially linking endocytic processes and actin cytoskeleton remodeling. The ALS2 C-terminal-like protein (ALS2CL) also modulates Rab 5 activity

Function:
May act as a GTPase regulator. Controls survival and growth of spinal motoneurons.

Subunit:
Forms a heteromeric complex with ALS2CL. Interacts with ALS2CL.

Post-translational modifications:
Phosphorylated upon DNA damage, probably by ATM or ATR.

DISEASE:
Defects in ALS2 are the cause of amyotrophic lateral sclerosis type 2 (ALS2) [MIM:205100]. ALS2 is a familial form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper and lower motor neurons and resulting in fatal paralysis. Sensory abnormalities are absent. Death usually occurs within 2 to 5 years. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of cases leading to familial forms. Defects in ALS2 are the cause of juvenile primary lateral sclerosis (JPLS) [MIM:606353]. JPLS is a neurodegenerative disorder which is closely related to but clinically distinct from amyotrophic lateral sclerosis. It is a progressive paralytic disorder which results from dysfunction of the upper motor neurons of the motor cortex while the lower neurons are unaffected.
Defects in ALS2 are the cause of infantile-onset ascending spastic paralysis (IAHSP) [MIM:607225]. IAHSP is characterized by progressive spasticity and weakness of limbs.

返回上一步
打印(yìn)此頁
[向上]

網(wǎng)站首(shǒu)頁(yè)

公(gōng)司介紹(shào)

產品中心

技術服務(wù)

技術文獻(xiàn)

在綫(xiàn)留(liú)言(yán)

聯係我們

在(zài)綫客(kè)服

咨(zī)詢電話(huà):

請掃描二維(wéi)碼
打(dǎ)開手(shǒu)機站